Literature DB >> 24887968

Peripheral nerve injury reduces analgesic effects of systemic morphine via spinal 5-hydroxytryptamine 3 receptors.

Masafumi Kimura1, Hideaki Obata, Shigeru Saito.   

Abstract

BACKGROUND: Morphine produces powerful analgesic effects against acute pain, but it is not effective against neuropathic pain, and the mechanisms underlying this reduced efficacy remain unclear. Here, the authors compared the efficacy of systemic morphine between normal rats and rats with peripheral nerve injury, with a specific focus on descending serotonergic mechanisms.
METHODS: After L5 spinal nerve ligation injury, male Sprague-Dawley rats were subjected to behavioral testing, in vivo microdialysis of the spinal dorsal horn to determine serotonin (5-hydroxytryptamine [5-HT]) and noradrenaline release, and immunohistochemistry (n = 6 in each group).
RESULTS: Intraperitoneal administration of morphine (1, 3, or 10 mg/kg) produced analgesic effects in normal and spinal nerve ligation rats, but the effects were greater in normal rats (P < 0.001). Morphine increased 5-HT release (450 to 500% of the baseline), but not noradrenaline release, in the spinal dorsal horn via activation of serotonergic neurons in the rostral ventromedial medulla. Intrathecal pretreatment with ondansetron (3 μg), a 5-HT3 receptor antagonist, or 5,7-dihydroxytryptamine creatinine sulfate (100 μg), a selective neurotoxin for serotonergic terminals, attenuated the analgesic effect of morphine (10 mg/kg) in normal rats but increased the analgesic effect of morphine in spinal nerve ligation rats (both P < 0.05).
CONCLUSIONS: Systemic administration of morphine increases 5-HT levels in the spinal cord, and the increase in 5-HT contributes to morphine-induced analgesia in the normal state but attenuates that in neuropathic pain through spinal 5-HT3 receptors. The plasticity of the descending serotonergic system may contribute to the reduced efficacy of systemic morphine in neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24887968     DOI: 10.1097/ALN.0000000000000324

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  7 in total

Review 1.  Therapeutic Basis of Clinical Pain Modulation.

Authors:  Daniel R Kirkpatrick; Dan M McEntire; Zakary J Hambsch; Mitchell J Kerfeld; Tyler A Smith; Mark D Reisbig; Charles F Youngblood; Devendra K Agrawal
Journal:  Clin Transl Sci       Date:  2015-05-11       Impact factor: 4.689

2.  Mu and delta opioid receptors play opposite nociceptive and behavioural roles on nerve-injured mice.

Authors:  Miriam Martínez-Navarro; David Cabañero; Agnieszka Wawrzczak-Bargiela; Anne Robe; Claire Gavériaux-Ruff; Brigitte L Kieffer; Ryszard Przewlocki; Josep E Baños; Rafael Maldonado
Journal:  Br J Pharmacol       Date:  2020-02-10       Impact factor: 8.739

3.  Plasma and cerebrospinal fluid pharmacokinetics of ondansetron in humans.

Authors:  Manting D Chiang; Karen Frey; Chris Lee; Evan D Kharasch; Dani Tallchief; Christopher Sawyer; Jane Blood; Hyunmoon Back; Leonid Kagan; Simon Haroutounian
Journal:  Br J Clin Pharmacol       Date:  2020-06-30       Impact factor: 4.335

4.  Adjunctive effect of the serotonin 5-HT2C receptor agonist lorcaserin on opioid-induced antinociception in mice.

Authors:  Salvador Sierra; Kumiko M Lippold; David L Stevens; Justin L Poklis; William L Dewey; Javier González-Maeso
Journal:  Neuropharmacology       Date:  2020-01-24       Impact factor: 5.273

5.  Dezocine exhibits antihypersensitivity activities in neuropathy through spinal μ-opioid receptor activation and norepinephrine reuptake inhibition.

Authors:  Yong-Xiang Wang; Xiao-Fang Mao; Teng-Fei Li; Nian Gong; Ma-Zhong Zhang
Journal:  Sci Rep       Date:  2017-02-23       Impact factor: 4.379

6.  Hydrogen Sulfide Increases the Analgesic Effects of µ- and δ-Opioid Receptors during Neuropathic Pain: Pathways Implicated.

Authors:  Xue Bai; Gerard Batallé; Gianfranco Balboni; Olga Pol
Journal:  Antioxidants (Basel)       Date:  2022-07-04

Review 7.  Targeting Chemokines and Chemokine GPCRs to Enhance Strong Opioid Efficacy in Neuropathic Pain.

Authors:  Martina Vincenzi; Michele Stanislaw Milella; Ginevra D'Ottavio; Daniele Caprioli; Ingrid Reverte; Daniela Maftei
Journal:  Life (Basel)       Date:  2022-03-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.